Integrated Report 2018
Integrated Report
-------------
Company Introduction
Materiality
The driving force of Eisai: “human health care (hhc)”
Eisai’s Strengths
History of Eisai
Management Strategies
CEO Message
Value Creation Process and Flow
Medium-Term Business Plan ‘EWAY 2025’
Strategy for the Development of Human Resources
Interview: Seeking the Integration of ESG and Corporate Value
Financial Strategy
Value Creating Activities
Improving Access to Medicines (ATM)
Message from Corporate Officers in Charge of Neurology Area
Development of New Potential Dementia Treatments
Initiatives for Dementia Area -Offering Solutions that Go Beyond Providing Pharmaceuticals-
Message from Corporate Officers in Charge of Oncology Area
Global Business Activities
- Drug Creation Activities
- Production Activities
- Marketing Activities
Business Base (Related ESG)
Corporate Governance System
Interview with Outside Director
Board of Directors and Executive Officers
Compliance & Risk Management
Partnerships
Quality Assurance, Stable Supply, Safety Information Management for Products
Business with Consideration for the Global Environment
Initiatives for Achieving Sustainable Development Goals (SDGs) and Contributing to Global Compact
Appendix
Major Products
Consolidated Financial Highlights Results for Fiscal 2017
ESG Index
Major R&D Pipeline
Fundamental Knowledge and Terminology for Pharmaceutical Industry
Status of Shares
Corporate Profile / Editor’s Note for Integrated Report 2018
Page
of
Save this page
My favourite pages
Download center
Send to a friend
Help
Iframe content
Page
of
Powered by ©
Euroland.com
Page saved
Page already saved
Page deleted
No saved pages